Article

FDA gives go-ahead to foldable acrylic IOL

The FDA has approved Advanced Medical Optics’ (AMO) Tecnis IOL on an acrylic platform. AMO said it plans to release the Tecnis foldable acrylic IOL commercially in the United States and Europe this month.

The FDA has approved Advanced Medical Optics’ (AMO) Tecnis IOL on an acrylic platform. AMO said it plans to release the Tecnis foldable acrylic IOL commercially in the United States and Europe this month.

The company said the IOL has the same unique benefits as its Tecnis silicone IOL and added that the Tecnis lens reduces spherical aberration and improves functional vision in varying light conditions.

In a simulated night-driving study, patients viewing a rural road through a Tecnis lens identified a pedestrian hazard significantly sooner than through a traditional spherical IOL. The company’s lens also provided a 45-foot advantage in detection and identification distance, according to AMO.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.